Encouraging progress in clinical study

”During the quarter, the clinical study reached another significance milestone, and our Japanese partner Solasia Pharma K.K. took place on our shareholder list. The drug candidate arfolitixorin has been well tolerated at the second dose level in the ongoing phase Ib/II study in patients with metastatic colorectal cancer, which is highly significant given that preclinical studies have shown that higher doses may provide greater efficacy,” says CEO, Petter Segelman Lindqvist.